{"id":3294,"date":"2002-05-01T00:00:00","date_gmt":"2002-05-01T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/index.php\/2002\/05\/01\/pmnews1_5\/"},"modified":"2019-02-18T17:48:02","modified_gmt":"2019-02-18T17:48:02","slug":"pmnews1_5","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/","title":{"rendered":"Pharma Marketing News Vol. 1, No. 5 (May 2002)"},"content":{"rendered":"<p> Vol. 1, No. 5 * May 2002<br \/> Published by VirSci Corporation * www.virsci.com <\/p>\n<p> <b>Editorial<\/b><\/p>\n<hr\/>\n<p> <b>The Demise of Everything &#8220;E&#8221;?<\/b><br \/> by<br \/> John Mack<br \/> Pharma Marketing News Editor<br \/><a href=\"mailto:johnmack@virsci.com\">johnmack@virsci.com<\/a><\/p>\n<p> The dot-coms have come and gone. Pharma companies seem to be &#8220;de- commissioning&#8221; their e-business divisions. Managers are losing their &#8220;e&#8221; prefixes in  their titles. The vast unemployed victims of downsizing are eliminating the &#8220;e&#8221; words  from their resumes. Is this the end of everything &#8220;e&#8221; and the Internet? <\/p>\n<p> Obviously, something is going on and savvy people are being quoted as in  <\/p>\n<p> &#8220;I wouldn&#8217;t say the Internet&#8217;s a dirty word. But companies know  enough not to add &#8216;dot-com&#8217; to the ends of their names these days.&#8221; &#8212; Jay Hare, a partner in the technology industry group in PricewaterhouseCoopers&#8217;  Minneapolis office, quoted in the May 13 E-Commerce Times <\/p>\n<p>  Ha! That ploy is old news, so 20th century thinking! What&#8217;s the thinking and real  strategy that we need today? This month&#8217;s guest article by Filip Troicki provides  some pointers. <\/p>\n<p> I always thought that Pharma, being a latecomer to the Internet, would have  learned a lesson from the dot-coms and avoided all the &#8220;irrational exuberance.&#8221;  Articles like &#8220;The Truth About E-Health&#8221; in this month&#8217;s Pharmaceutical Executive  Magazine suggest that the industry has not been fully inoculated against the  &#8220;epidemic of weak ROI.&#8221; But just like the investor who was not fully exposed to stocks  during the boom and also not fully exposed during the bust, now may be a good  time for pharma marketers to &#8220;buy in&#8221; to the Internet, according to Troicki.  <\/p>\n<p> Yet there is still a fly in the ointment according to Edward Fotsch MD, author of the  PE article mentioned above and CEO of Medem. According to Fotsch, e-health  ROI for pharma has been a disaster because physicians have not embraced the  Internet and payors refuse to help by making it profitable for physicians to do so.  This, of course, is a physician-centric view of ROI. I am willing to concede that 85%  of all healthcare dollars are controlled by physicians&#8217; pens, but the healthcare  consumer is where the Internet action is. And the way things are going, consumers  will soon be deciding where more and more of that money will be spent (e.g.,  defined contribution health insurance plans). It is also well-known that consumers  can influence doctors&#8217; decisions, especially after visiting a product website ( a  recent survey by Vividence found that after visiting a product web site 72% of  consumers would likely request the drug from their physicians compared to 38%  before visiting the site). This increasing patient awareness and empowerment, which  the Internet enhances, is the premise on which DTC advertising and promotion is  based.  <\/p>\n<p> Consumer empowerment facilitated by the Internet has the capability of changing  how huge companies &#8212; like the music industry &#8212; do business. But the music industry  wants to resist the change and has called upon the Feds to help them. Pharma,  being a heavily regulated industry, knows all too well the danger of bringing in the  Feds &#8212; sooner or later it&#8217;s going to be payback time! Better to have a strategy to  meet the challenge on your own terms. And this is precisely the opportunity before  pharma with regard to the patient-physician &#8220;battle&#8221; over empowerment in which the  Internet is playing a huge role. <\/p>\n<p> Consumers demand information, convenience, and transparency that the Internet is  designed to offer. IMHO, many doctors can&#8217;t be bothered with the whole thing and  wish it would just go away. But it won&#8217;t. <\/p>\n<p> So, you (pharma marketers) can spend all your big bucks earmarked for the Internet  trying to reach physicians until you are blue in the face and you will never get the  kind of ROI you are used to with traditional methods of physician-focused  promotion. I think you should have learned this lesson a long time ago before the  Internet was so ubiquitous &#8212; all the pre-Internet technological schemes to reach  physicians by computer (and even TV) were failures also. I predict that wireless\/PDA  applications and promotional gimmicks and e-detailing aimed at physicians will  also cost the industry big bucks and fail the ROI test as well. <\/p>\n<p> Now, I&#8217;m not saying that pharma marketers should choose sides and pick consumers  over doctors. OK, maybe I am &#8212; but only on the Internet or when using any kind of  technology. That&#8217;s my viewpoint and I&#8217;m sticking to it!  <\/p>\n<\/p>\n<hr\/>\n<p><b>ADVERTISEMENT<\/b><\/p>\n<hr\/>\n<p>  <img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2002\/05\/FPW_bnnr-1.jpg\" width=\"500\" height=\"114\" border=\"1\" alt=\"Pharma NetTRUST Federal Privacy Watch\"\/><\/p>\n<p> <a href=\"http:\/\/www.virsci.com\/pharmaNetTRUST\/FPW-hp.html\">Pharma NetTRUST Federal Privacy Watch<\/a> (FPW) is a periodic, subscription-based  e-newsletter with up-to-date news about privacy laws, regulations, and actions by  Congress and federal agencies of interest to pharmaceutical companies. FPW  reports include:  <\/p>\n<ul>\n<li>summaries and status of proposed and enacted legislation  <\/li>\n<li>Federal Trade Commission (FTC) and other federal agency actions  <\/li>\n<li>healthcare and pharma industry response to legislation, press releases,  position statements, etc.  <\/li>\n<li>privacy advocate organization opinions, press reports and views on  legislation  <\/li>\n<li>European Union (EU) privacy laws affecting US pharma companies, safe  harbor news, and effects on US legislation and policy  <\/li>\n<\/ul>\n<p> Read a <a href=\"http:\/\/www.virsci.com\/pharmaNetTRUST\/fpw1_1.html\">complimentary issue<\/a> and learn about the latest proposed privacy legislation and FTC comments. For  subscription information, call John Mack at 215-504-4164 or e-mail  <a href=\"mailto:johnmack@virsci.com\">johnmack@virsci.com<\/a>. <\/p>\n<\/p>\n<hr\/>\n<p> <b>Guest Article<\/b><\/p>\n<hr\/>\n<p> <b>E-marketing must follow e-strategy<\/b><br \/> by<br \/> Filip Troicki, VP, Research &amp; Analysis, Vessel Media LLC<br \/><a href=\"mailto:filip@vesselmedia.com\">filip@vesselmedia.com<\/a>  <\/p>\n<p> The beginning of 2002 brought about some positive signs of activity in the e-health  marketing arena. One of the reasons for the positive outlook has to do with the fact  that the online businesses that got through the industry&#8217;s toughest times are stronger  and have created more to offer their audiences and their advertisers. The survivors  are the Web properties that have solid content, innovative services, sticky  audiences, and an ability to quickly adapt to change. As the Internet is emerging  from the fog, the healthcare industry is also slowly warming up to the idea of  revisiting the medium for marketing initiatives. The activity of pharmaceutical  companies has been largely limited to small tests on well-known portals, followed by  close analysis of the ROI for each campaign. At a time when some pharmaceutical  marketers see themselves as giving the Internet a &#8220;second chance,&#8221; most Web  portals are hoping that the &#8220;second chance&#8221; will not be their last. It would be in  everyone&#8217;s best interest if these online tests produce good results and online  advertising campaigns develop into marketing programs that rival those of  traditional media.  <\/p>\n<p> <b>E-CONFUSION<\/b>  <\/p>\n<p> Pharmaceutical e-marketing teams have not had an easy task navigating the online  waters in recent years. After the major pharmaceutical brands limited their overall  marketing budgets during the past 18 months, online healthcare advertising came  to a virtual standstill. In what seemed to be a never ending and self-fulfilling cycle,  most marketers began to decrease online spending after they saw the poor results of  their initial online advertising campaigns. The evaporation of advertising revenues  to Web sites caused major changes that greatly affected the topography of the e- health space. The changes that included the disappearance of giants like  DrKoop.com, the acquisition of Medscape by WebMD, and the downsizing of many  other health portals, has caused many pharmaceutical marketers to be skeptical  about the stability of the Internet. As more portals closed their doors, got acquired,  or were downsized, marketers again tightened their advertising budgets and the  cycle began again. While the scenario is not as simple as I have just described it, it  does point out a set of events that healthcare e-marketers were forced to deal with,  until recently. The demise of Internet properties with poor business models has  cleared the air for those properties with strong foundations to flourish. As a result,  those left standing are more determined than ever to create programs that fulfill  advertiser&#8217;s marketing objectives.   <\/p>\n<\/p>\n<hr\/>\n<p><b>ADVERTISEMENT<\/b><\/p>\n<hr\/>\n<p> <b> Pharmaceutical Marketing Congress<\/b>  <\/p>\n<p> <b>SEPTEMBER 30 &#8211; OCTOBER 2, 2002<br \/>  WYNDHAM FRANKLIN PLAZA HOTEL, PHILADELPHIA<\/b> <\/p>\n<p>  In light of growing challenges and major shifts in the healthcare landscape, we are  pleased to announce The 2002 Pharmaceutical Marketing Congress, the most  comprehensive, multi-track pharmaceutical industry conference to date addressing  state-of-the-art marketing strategies to successfully reach and meet the needs of the  entire spectrum of customers. <\/p>\n<p> CONFERENCE WEB SITE: <a href=\"http:\/\/www.iirusa.com\/pharmaevent\/\">www.iirusa.com\/pharmaevent\/<\/a> <\/p>\n<hr\/>\n<p>  <b>NOW IS THE TIME FOR STRATEGY<\/b>  <\/p>\n<p> Imagine putting a plan together where the Internet marketing budget gets allocated  more money than print or TV. If this sounds far fetched, it shouldn&#8217;t. The Internet  allows for direct interaction with precise target audiences, making it a much more  powerful medium for advertising than print or TV. The marketers who are able to  appreciate the power of the Internet will want to take advantage of this medium at a  time when everyone else is being skeptical.   <\/p>\n<p> This is the time to be online. The turmoil of the past three years has caused many  Web sites to drop their ad rates considerably, accepting campaigns that are  sometimes 90% below the 1999 rate card. Most Web sites have also come up with  more innovative marketing solutions and have upgraded their ad serving software  with the capability of targeting specific audiences. Armed with wisdom of past  experience, and presented with opportunities that are both innovative and  affordable, it is surprising that not everyone is taking advantage of the Internet. What  is even more surprising is that those marketers who decided to return to the Internet  continue to rely on the same tactics that drove them away from the Web in the first  place.   <\/p>\n<p> Pharmaceutical marketers continue to place banner buys on the most popular Web  sites without putting much emphasis on strategy. They fail to realize that online  marketing is not just banners and buttons but an opportunity to interact with,  educate, and influence their target physicians and consumers through multiple  media channels. At the end of the day what matters most is how many prescriptions  are written and not whether a physician or patient clicks on a banner. It is crucial to  look at the results of an online advertising campaign in the light of the strategy that  was developed when planning the campaign. At the risk of sounding too obvious, I  need to point out that the consequences of a poor strategy are poor results.  Pharmaceutical marketers need to put more effort into looking at the opportunities  available on the Internet and see how these opportunities fit in with their marketing  goals. When used correctly, the Internet can be used as a powerful tool that delivers  excellent results.   <\/p>\n<p> <b>WHY MARKET ON THE INTERNET?<br \/>Because your customers are already there.<\/b>  <\/p>\n<p> According to the September 2001 Boston Consulting Group study, 89% of  physicians are already online, and an effective e-marketing strategy has a  significant influence on the prescribing behavior of 73% of physicians. In a  September 2001 study done by International Communications Research for the  Kaiser Family Foundation, 75% of consumers are online using the Web to research  drug and disease state information. A recent study by Vividence Corporation also  reveals that 72% of those consumers request medications from their physicians after  learning about the drug on the Internet. These studies show the power of the  Internet is such that even the smallest pharmaceutical companies with the least  known drugs can outperform and outsell the giants. If this is the case, why are so few  pharmaceutical companies taking advantage of the Internet? The problem mainly  lies in the fact that the power of the Internet has been fogged up by the sheer  quantity of healthcare Web sites and opportunities available for promoting products  online. With all the other opportunities that pharmaceutical marketers have come to  know and trust offline, not many have the time to learn about the opportunities of  this new medium. As with any other medium, in order to come up with a successful  online advertising campaign, the pharmaceutical managers will need to do their  homework and learn about the opportunities available online.   <\/p>\n<p> As the Internet clutter begins to clear, innovative online marketing tools are being  introduced and online advertising rates have dropped. Advertisers who can quickly  dominate the field will be the first to reap the benefits of brand loyalty and new  customer acquisitions. The challenge for pharmaceutical marketers is not only to  learn about the opportunities available on the Web, but also to take advantage of  those opportunities to dominate this space before competitors swallow up the  limited inventory. Pharmaceutical companies that can quickly and effectively  integrate e-strategies into their offline marketing initiatives will be able to influence  vast audiences that are looking for guidance and information on the Internet. We  have seen many pharmaceutical marketers refuse to incorporate their offline  promotions with online advertising campaigns, only to come back and point out that  their competitors have saturated the online space. As the Internet space again fills  with the same old banner ads and buttons, it will be those companies that can  come up with innovative strategies to target their consumers that will ultimately  succeed online. As I previously mentioned, what matters is not impressions and  clicks, but interaction with exact target audiences to the point of product  recommendation, evaluation, and finally treatment &#8212; all with the pharmaceutical  brand in mind. To illustrate the importance of a winning online marketing strategy,  allow me to give an example.   <\/p>\n<p> A pharmaceutical company planning a Phase III clinical trial decided to use the  Internet as one of the tools to recruit patients. The first attempt at recruiting a  sizable group was through banner advertising on major health portals. The  campaign lasted over 2 months cost the pharmaceutical company more than  anyone wanted to admit. The second attempt was an email strategy that relied on  rentals of cheap email inventory and blasting out mass emails to unknown  audiences. The results of the email campaign also turned out to be poor, and we  were called in to evaluate the problems and come up with a solution. The problem  we saw with the banner campaigns is that they were ignored by most of the  audiences. Banner advertising is usually a better tool for branding than it is for  clinical trial recruitment. Non-targeted emails did not serve their purpose especially  since the audience was not pre-qualified in any way before the emails were sent. At  the time when we were called in, the budget was already largely spent, and the  time allocated for the recruitment was quickly coming to an end. After evaluating  results of the previous campaigns, and keeping in mind the goals set by the  pharmaceutical company, we were able to come up with an effective and efficient  solution. As usual, the inclusion\/exclusion list was lengthy but the time allocated for  the recruitment was not. On a limited budget, our strategy was a cost per lead email  campaign that targeted the inclusion group, and listed the perimeters of the  exclusion list. In order for the lead to be considered valid, each individual had to  check off the correct information that listed the exclusions. The leads that came  back were re-evaluated and the prospective patients were sent for screenings at  nearby medical centers. We were able to get a sufficient number of leads in a  single week, and since we only paid for the recruited patients, the cost was about  50% lower than the budget.   <\/p>\n<p> What is interesting about this campaign is that it proved to be so successful after two  previous failed attempts by the pharmaceutical company to recruit patients via  other channels on the Internet. The pharmaceutical company described above is  not necessarily a typical scenario, since most companies would have given up after  the first unsuccessful online campaign, but it does illustrate how a well-planned  Internet strategy can provide great results. The wisdom behind a successful online  strategy is seeking out and targeting the right audience, and developing tools that  ensure that the audience is both interested and receptive.   <\/p>\n<p> An online marketing strategy should include a number of essential steps to insure  the campaign&#8217;s success. We have seen that companies that follow these steps are  usually on the right track to successful online marketing campaigns:  <\/p>\n<\/p>\n<ol>\n<li>Education about the overall opportunities on the Internet. <\/li>\n<li>Research about healthcare industry and how it pertains to your  product <\/li>\n<li>Planning of targeted, results driven online marketing strategies <\/li>\n<li>Implementation of test campaigns <\/li>\n<li>Optimization of campaigns <\/li>\n<li>Analysis of results through detailed reports <\/li>\n<\/ol>\n<p> Even though the online world might seem overwhelming and unstable, and many  pharmaceutical companies try hard to avoid it, it will be the early adapters and the  risk takers that profit from being online. Not only does the Internet provide a way to  reach virtually any audience, it also allows for pharmaceutical companies to  interact with their target audiences and influence their behavior. With 89% of  physicians and 75% of consumers currently online, it&#8217;s time for the pharmaceutical  industry to start planning effective online strategies that grab the attention of their  customers, and increase their marketing ROI.                                                                                                        <\/p>\n<\/p>\n<hr\/>\n<p><b>PRESENTATIONS<\/b><\/p>\n<hr\/>\n<p>  <b>HIPAA Compliance for Pharmaceutical Manufacturers, PBMs and Pharmacies<\/b> <\/p>\n<p> <b>Jean-Paul Hepp<\/b>, Director Global Privacy, Pharmacia<br \/><b>John Mack<\/b>, President, VirSci Corporation <\/p>\n<p> 3:00 PM * June 21, 2002 * <b>ETHIC 2002<\/b> * Hilton Washington &amp; Towers * Washington, DC <\/p>\n<\/p>\n<p>  For more information about this presentation and conference (including registration), call 800-640-2218 or visit <a href=\"http:\/\/www.ethic2002.com\">www.ethic2002.com<\/a>. <\/p>\n<\/p>\n<p> * * * *  <\/p>\n<p>  <b>Preparing Your Pharmaceutical Company for HIPAA: Compliance and Beyond<\/b> <\/p>\n<p> <b>John Mack<\/b>, President, VirSci Corporation<br \/><b>Lois C. Ambash<\/b>, Principal, e-Health Partners<br \/><b>Jon Bogen<\/b>, CEO, HealthCIO<\/p>\n<p> 8:30 AM * August 5, 2002 * <b>HIPAA for Pharmaceuticals<\/b> * Hilton Washington &amp; Towers * Washington, DC <\/p>\n<\/p>\n<p> This workshop is designed to provide practical guidance for Pharmaceutical,  Biotech and Medical Device Companies who are in the planning or very early  stages of HIPAA compliance. It&#8217;s premise is that the process of HIPAA compliance  can be leveraged to help solve larger organizational and business challenges. <\/p>\n<p> For more information about this presentation and conference (including registration), call 888-670-8200 or visit <a href=\"http:\/\/www.iirusa\/hipaapharma\">www.iirusa\/hipaapharma<\/a>.   <\/p>\n<p> <b>ABOUT Pharma Marketing News<\/b><\/p>\n<hr\/>\n<p> Pharma Marketing News is a monthly publication sponsored by <a href=\"http:\/\/www.virsci.com\">VirSci Corporation (www.virsci.com)<\/a> and  distributed FREE to subscribers of the PHARMA-MKTING e-mail discussion group.  PHARMA-MKTING is an exclusive email network for pharmaceutical marketing professionals interested in the latest interactive technologies available for marketing. The  network facilitates communication between members and recognized experts and leaders in  interactive pharmaceutical marketing. See <a href=\"http:\/\/www.pharma-mkting.com\">www.pharma-mkting.com<\/a> for more information about becoming a member of the group.   <\/p>\n<p> <b>ABOUT VirSci Corporation<\/b><\/p>\n<hr\/>\n<p> VirSci (pronounced VER &#8211; sigh) is dedicated to developing and applying best practices in  privacy, usability, and quality to online pharmaceutical and health marketing. It&#8217;s our  passion to help our clients do business via the Internet more effectively, with greater return  on investment, and with enhanced consumer trust. VirSci provides global pharmaceutical  and healthcare industry clients with competitive market intelligence, interactive marketing  services, and HIPAA\/privacy\/security consulting and educational services <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PHARMA MARKETING NEWS is the periodic newsletter of the PHARMA-MKTING email discussion group. It includes original articles, opinions from leaders in the field of interactive pharmaceutical marketing, industry news briefs, and useful information abstracted from subscriber discussion threads. The dot-coms have come and gone. Pharma companies seem to be de-commissioning their e-business divisions. Managers are losing their e prefixes in their titles. The vast unemployed victims of downsizing are eliminating the e words from their resumes. Is this the end of everything e and the Internet? Is it a waste of time and money using technology, including the Internet and wireless PDA applications, to reach physicians? Is it about time that pharmaceutical marketers reverse the lopsided budget spent on physicians vs consumers, at least when it comes to the Internet and other high technology channels?<\/p>\n","protected":false},"author":2,"featured_media":3298,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[51,6],"tags":[],"topic":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma Marketing News Vol. 1, No. 5 (May 2002) - Pharma Marketing Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma Marketing News Vol. 1, No. 5 (May 2002) - Pharma Marketing Network\" \/>\n<meta property=\"og:description\" content=\"PHARMA MARKETING NEWS is the periodic newsletter of the PHARMA-MKTING email discussion group. It includes original articles, opinions from leaders in the field of interactive pharmaceutical marketing, industry news briefs, and useful information abstracted from subscriber discussion threads. The dot-coms have come and gone. Pharma companies seem to be de-commissioning their e-business divisions. Managers are losing their e prefixes in their titles. The vast unemployed victims of downsizing are eliminating the e words from their resumes. Is this the end of everything e and the Internet? Is it a waste of time and money using technology, including the Internet and wireless PDA applications, to reach physicians? Is it about time that pharmaceutical marketers reverse the lopsided budget spent on physicians vs consumers, at least when it comes to the Internet and other high technology channels?\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Marketing Network\" \/>\n<meta property=\"article:published_time\" content=\"2002-05-01T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-18T17:48:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2002\/05\/FPW_bnnr-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"114\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pharma Guy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pharma Guy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/\",\"url\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/\",\"name\":\"Pharma Marketing News Vol. 1, No. 5 (May 2002) - Pharma Marketing Network\",\"isPartOf\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\"},\"datePublished\":\"2002-05-01T00:00:00+00:00\",\"dateModified\":\"2019-02-18T17:48:02+00:00\",\"author\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\"},\"breadcrumb\":{\"@id\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma Marketing News Vol. 1, No. 5 (May 2002)\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\",\"name\":\"Pharma Marketing Network\",\"description\":\"Pharma Marketing Network\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\",\"name\":\"Pharma Guy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/\",\"url\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"contentUrl\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"caption\":\"Pharma Guy\"},\"description\":\"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharma Marketing News Vol. 1, No. 5 (May 2002) - Pharma Marketing Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/","og_locale":"en_US","og_type":"article","og_title":"Pharma Marketing News Vol. 1, No. 5 (May 2002) - Pharma Marketing Network","og_description":"PHARMA MARKETING NEWS is the periodic newsletter of the PHARMA-MKTING email discussion group. It includes original articles, opinions from leaders in the field of interactive pharmaceutical marketing, industry news briefs, and useful information abstracted from subscriber discussion threads. The dot-coms have come and gone. Pharma companies seem to be de-commissioning their e-business divisions. Managers are losing their e prefixes in their titles. The vast unemployed victims of downsizing are eliminating the e words from their resumes. Is this the end of everything e and the Internet? Is it a waste of time and money using technology, including the Internet and wireless PDA applications, to reach physicians? Is it about time that pharmaceutical marketers reverse the lopsided budget spent on physicians vs consumers, at least when it comes to the Internet and other high technology channels?","og_url":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/","og_site_name":"Pharma Marketing Network","article_published_time":"2002-05-01T00:00:00+00:00","article_modified_time":"2019-02-18T17:48:02+00:00","og_image":[{"width":500,"height":114,"url":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2002\/05\/FPW_bnnr-1.jpg","type":"image\/jpeg"}],"author":"Pharma Guy","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pharma Guy","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/","url":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/","name":"Pharma Marketing News Vol. 1, No. 5 (May 2002) - Pharma Marketing Network","isPartOf":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website"},"datePublished":"2002-05-01T00:00:00+00:00","dateModified":"2019-02-18T17:48:02+00:00","author":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1"},"breadcrumb":{"@id":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmnews1_5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/"},{"@type":"ListItem","position":2,"name":"Pharma Marketing News Vol. 1, No. 5 (May 2002)"}]},{"@type":"WebSite","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/","name":"Pharma Marketing Network","description":"Pharma Marketing Network","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1","name":"Pharma Guy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/","url":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","contentUrl":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","caption":"Pharma Guy"},"description":"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/"}]}},"_links":{"self":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/3294"}],"collection":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/comments?post=3294"}],"version-history":[{"count":1,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/3294\/revisions"}],"predecessor-version":[{"id":3299,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/3294\/revisions\/3299"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media\/3298"}],"wp:attachment":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media?parent=3294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/categories?post=3294"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/tags?post=3294"},{"taxonomy":"topic","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/topic?post=3294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}